EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Regeneron Pharmaceuticals's enterprise value is $90,661 Mil.
Regeneron Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $13,117 Mil. Therefore, Regeneron Pharmaceuticals's EV-to-Revenue for today is 6.91.
The historical rank and industry rank for Regeneron Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
REGN'
s EV-to-Revenue Range Over the Past 10 Years
Min: 3.65 Med: 8.05 Max: 20.08
Current: 6.91
During the past 13 years, the highest EV-to-Revenue of Regeneron Pharmaceuticals was 20.08. The lowest was 3.65. And the median was 8.05.
REGN's EV-to-Revenue is ranked better than 52.28% of 1031
companies
in the Biotechnology industry
Industry Median: 7.7
vs REGN: 6.91
As of today (2024-04-23), Regeneron Pharmaceuticals's stock price is $907.32.
Regeneron Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $115.32. Therefore, Regeneron Pharmaceuticals's PS Ratio for today is 7.87.
Regeneron Pharmaceuticals EV-to-Revenue Historical Data
The historical data trend for Regeneron Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Regeneron Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's EV-to-Revenue falls into.
Regeneron Pharmaceuticals's current Enterprise Value is $90,661 Mil.
Regeneron Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $13,117 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals's share price for today is $907.32.
Regeneron Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $115.32.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
REGN has been successfully added to your 